BioArctic receives European patent for new antibodies targeting Alzheimer's disease |
| January 27, 2021 | January 2021 Bond Updates |
|
STOCKHOLM, Jan. 27, 2021 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to grant European patent EP 2 448 968 B1 for novel antibodies that could be developed into a treatment for Alzheimer's... |
| View more at: https://www.prnewswire.com:443/news-releases/bioarctic-receives-european-patent-for-new-antibodies-targeting-alzheimers-disease-301215908.html |